Tous Actualités
Suivre
Abonner ProMetic Life Sciences

ProMetic Life Sciences

Alliance Between MacoPharma, ProMetic and PRDT Leads to New Advances in Prion Removal Filter

LILLE, France and MONTREAL, Québec, June 28 (ots/PRNewswire)

The
latest scientific data on MacoPharma's prion filter device will be
presented at the XV European Regional Congress of the International
Society of Blood Transfusion (ISBT) being held in Athens, Greece on
July 4, 2005, MacoPharma and ProMetic Life Sciences Inc. ("ProMetic")
(TSX: PLI.SV) announced today.
The significant advances in prion removal will be disclosed during
a symposium organised by MacoPharma and titled "An Innovative
Approach for the Reduction of vCJD Transmission in the Blood Supply".
The symposium will feature Dr. Richard Knight, member of the National
Creutzfeldt-Jakob Disease Surveillance Unit, UK, Dr. Chris Prowse,
Research & Development Director, Scottish National Blood Transfusion
Service, Scotland, and Dr. Robert G. Rohwer, Director of the
Molecular Neurovirology Laboratory, University of Maryland, USA. The
speakers will present a global overview of the vCJD epidemic and the
implications and risks associated with vCJD in Transfusion Medicine.
Dr. Rohwer, a world-renowned expert in the field of TSE
(Transmissible Spongiform Encephalopathy) diseases, will detail the
validation of a filter for the reduction of vCJD transmission through
blood as well as its key capabilities:
-  99.99% removal of infectivity;
    -  Binding and removal of infectious agents from human vCJD brain and
       hamster scrapie brain present in leukodepleted red blood cell
       concentrate, whole blood and plasma;
    -  Minimal loss of red blood cells.
Dr Rohwer will also present data from an ongoing endogenous
infectivity study which to date demonstrates blood-borne prion
removal from whole blood.
Prion removal technology is an initiative of Pathogen Removal and
Diagnostic Technologies Inc. ("PRDT"), a joint venture between
ProMetic and the American Red Cross ("ARC"). MacoPharma has
incorporated this technology to provide an innovative filter for
prion removal from blood components. PRDT and MacoPharma firmly
believe that prion removal from the blood supply is the most
appropriate approach toward the reduction and elimination of the
potential risk of vCJD contamination.
MacoPharma's prion removal filter, P-Capt(TM), should obtain CE
registration later this year, "an important milestone that will allow
pan- European marketing of this medical device. We are now focused on
satisfying the additional requirements of blood authorities. This
includes their technical, operational and component specifications,
performing a clinical study, and meeting operational validation
requirements," said Mr. François Bidet, Strategic Marketing Manager
at MacoPharma.
"The P-Capt prion removal filter has shown no effect on red cell
haemolysis or stability, nor on plasma protein levels or platelet
activation. This is an essential requirement of the blood processing
industry," stated Dr. Peter Edwardson, Project Director, PRDT.
MacoPharma, a European industry leader in blood collection systems
and transfusion solutions, expects to market the prion filter at the
end of 2005. Initially, it will be a device which can be attached to
any existing blood collection system following leukodepletion of red
blood cell concentrate in the presence of additive solution or
plasma.
About PRDT
PRDT is a joint-venture company set up in April 2002 by the
American Red Cross and ProMetic Life Sciences Inc. PRDT allows for a
reciprocal exchange of technology and a knowledge base developed
between the American Red Cross and ProMetic. PRDT's main goal is to
develop products and devices to remove and detect different pathogens
from biological sources. This research augments work that ProMetic,
the American Red Cross and PRDT's scientific founders have been
conducting independently for many years
About ProMetic Life Sciences
ProMetic Life Sciences Inc. (TSX: PLI.SV) is a biopharmaceutical
company specialised in the research, development, manufacture and
marketing of a variety of commercial applications derived from its
proprietary enabling technology. Mimetic Ligand(TM) technology is
used in large-scale purification of biologics and the elimination of
pathogens. ProMetic is also active in therapeutic drug development
with the mission to bring to market effective, innovative, lower
cost, less toxic products for the treatment of inflammation and
cancer. The Company's Mimetic Ligand TM technology is also leveraged
into its drug discovery platform aiming at replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics.
Headquartered in Montreal (Canada), ProMetic has R&D and
manufacturing facilities in the UK and business development
activities in the US, Europe, Asia and MENA countries (Middle East
and North Africa). Additional information is available on the
Company's website: www.prometic.com.
About MacoPharma
MacoPharma is an innovator in global healthcare with expertise in
the fields of Transfusion and Infusion. The Company has become the
largest supplier of in-line leukoreduction filtration sets in Europe
and is expanding its efforts into the biotherapy field by developing
products for cell expansion, in addition to cell/organ processing and
freezing. Headquartered in the Lille metropolitan area (France),
MacoPharma has three manufacturing facilities in Europe and its
products are now sold into more than 55 countries worldwide. One of
MacoPharma's aims is to provide a comprehensive range for the
reduction of infectious agents in plasma, platelets and red cells.
This is conducive with the MacoPharma product development strategy of
the continuous quest, through partnerships, for improved safety,
efficacy, and quality of transfusion, infusion and biotherapy. For
more information: www.macopharma.com.
This press release contains forward-looking statements that
involve risks and uncertainties, including, but not limited to
ProMetic's ability to develop, manufacture, and successfully
commercialise value-added pharmaceutical products and to obtain
contracts for its products and services and commercial acceptance of
advanced affinity separation technology. Shareholders are cautioned
that these statements are predictions and these actual events or
results may differ materially from those anticipated in these
forward-looking statements.

Contact:

For further information: MacoPharma: Iwona Walicka, Project Manager,
Strategic Marketing, +33(0)3-20-11-85-31,
iwona.walicka@macopharma.com; ProMetic Life Sciences Inc.:
Communications, Sylvie Gosselin, Communications Manager,
+1(514)-341-2115, s.gosselin@prometic.com; Analysts & Institutional
Investors, Nicole Blanchard, President, Sun International
Communications, +1(450)627-6600, nicole.blanchard@isuncomm.com;
Media: Dominic Sicotte, President, Echoes Media Relations Inc.,
+1(514)-842-9551, Toll free: +1-866-633-9551, dsicotte@echoesmedia.tv

Plus de actualités: ProMetic Life Sciences
Plus de actualités: ProMetic Life Sciences
  • 24.09.2004 – 23:47

    ProMetic Modifies its Organisational Structure

    Montreal (ots/PRNewswire) - ProMetic Life Sciences (PLI:TSX) announced today the administrative reorganisation of its communications and business development structure. By implementing these changes, the Company is focusing its business development activities in key markets providing optimal growth opportunities namely in the United States, Europe, Asia and the Middle East. ProMetic can better achieve this goal ...

  • 02.09.2004 – 13:36

    Prometic's Lead Cancer Compound PBI-1402 Has Confirmed Activity on Red Blood Cell Progenitors

    Montreal (ots/PRNewswire) - - Potential use Includes Anaemia Induced by Chemotherapy and Renal Diseases - Market of Above US$10 Billion ProMetic Life Sciences Inc. (TSX: PLI) is pleased to announce that its scientists have confirmed evidence of PBI-1402's positive effect on the formation of red blood cells in bone marrow. This proliferation is additive ...